Current and future trends in biomarker discovery and development of companion diagnostics for arthritis

David Gibson, Michael Bustard, Cathy McGeough, Helena A Murray, Martin A Crockard, Andrew Mc Dowell, Jayne Blayney, Philip Gardiner, AJ Bjourson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Musculoskeletal diseases such as rheumatoid arthritis are complex multifactorial disorders that are chronic in nature and debilitating for patients. A number of drug families are available to clinicians to manage these disorders but few tests exist to target these to the most responsive patients. As a consequence, drug failure and switching to drugs with alternate modes of action is common. In parallel, a limited number of laboratory tests are available which measure biological indicators or ‘biomarkers’ of disease activity, autoimmune status, or joint damage. There is a growing awareness that assimilating the fields of drug selection and diagnostic tests into ‘companion diagnostics’ could greatly advance disease management and improve outcomes for patients. This review aims to highlight: the current applications of biomarkers in rheumatology with particular focus on companion diagnostics; developments in the fields of proteomics, genomics, microbiomics, imaging and bioinformatics and how integration of these technologies into clinical practice could support therapeutic decisions.
LanguageEnglish
JournalExpert Review of Molecular Diagnostics
Volume15
Issue number2
DOIs
Publication statusPublished - 2015

Fingerprint

Arthritis
Biomarkers
Pharmaceutical Preparations
Drug Substitution
Musculoskeletal Diseases
Rheumatology
Disease Management
Genomics
Computational Biology
Routine Diagnostic Tests
Proteomics
Autoimmune Diseases
Rheumatoid Arthritis
Joints
Technology
Therapeutics

Keywords

  • Bioinformatics
  • Companion Diagnostics
  • Genomics ,
  • Microbiomics
  • Stratified Medicine
  • Arthritis

Cite this

Gibson, David ; Bustard, Michael ; McGeough, Cathy ; Murray, Helena A ; Crockard, Martin A ; Mc Dowell, Andrew ; Blayney, Jayne ; Gardiner, Philip ; Bjourson, AJ. / Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. In: Expert Review of Molecular Diagnostics. 2015 ; Vol. 15, No. 2.
@article{87d52f37080e4acb86adbb628229fa66,
title = "Current and future trends in biomarker discovery and development of companion diagnostics for arthritis",
abstract = "Musculoskeletal diseases such as rheumatoid arthritis are complex multifactorial disorders that are chronic in nature and debilitating for patients. A number of drug families are available to clinicians to manage these disorders but few tests exist to target these to the most responsive patients. As a consequence, drug failure and switching to drugs with alternate modes of action is common. In parallel, a limited number of laboratory tests are available which measure biological indicators or ‘biomarkers’ of disease activity, autoimmune status, or joint damage. There is a growing awareness that assimilating the fields of drug selection and diagnostic tests into ‘companion diagnostics’ could greatly advance disease management and improve outcomes for patients. This review aims to highlight: the current applications of biomarkers in rheumatology with particular focus on companion diagnostics; developments in the fields of proteomics, genomics, microbiomics, imaging and bioinformatics and how integration of these technologies into clinical practice could support therapeutic decisions.",
keywords = "Bioinformatics, Companion Diagnostics, Genomics ,, Microbiomics, Stratified Medicine, Arthritis",
author = "David Gibson and Michael Bustard and Cathy McGeough and Murray, {Helena A} and Crockard, {Martin A} and {Mc Dowell}, Andrew and Jayne Blayney and Philip Gardiner and AJ Bjourson",
year = "2015",
doi = "10.1586/14737159.2015.969244",
language = "English",
volume = "15",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
number = "2",

}

Current and future trends in biomarker discovery and development of companion diagnostics for arthritis. / Gibson, David; Bustard, Michael; McGeough, Cathy; Murray, Helena A; Crockard, Martin A; Mc Dowell, Andrew; Blayney, Jayne; Gardiner, Philip; Bjourson, AJ.

In: Expert Review of Molecular Diagnostics, Vol. 15, No. 2, 2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Current and future trends in biomarker discovery and development of companion diagnostics for arthritis

AU - Gibson, David

AU - Bustard, Michael

AU - McGeough, Cathy

AU - Murray, Helena A

AU - Crockard, Martin A

AU - Mc Dowell, Andrew

AU - Blayney, Jayne

AU - Gardiner, Philip

AU - Bjourson, AJ

PY - 2015

Y1 - 2015

N2 - Musculoskeletal diseases such as rheumatoid arthritis are complex multifactorial disorders that are chronic in nature and debilitating for patients. A number of drug families are available to clinicians to manage these disorders but few tests exist to target these to the most responsive patients. As a consequence, drug failure and switching to drugs with alternate modes of action is common. In parallel, a limited number of laboratory tests are available which measure biological indicators or ‘biomarkers’ of disease activity, autoimmune status, or joint damage. There is a growing awareness that assimilating the fields of drug selection and diagnostic tests into ‘companion diagnostics’ could greatly advance disease management and improve outcomes for patients. This review aims to highlight: the current applications of biomarkers in rheumatology with particular focus on companion diagnostics; developments in the fields of proteomics, genomics, microbiomics, imaging and bioinformatics and how integration of these technologies into clinical practice could support therapeutic decisions.

AB - Musculoskeletal diseases such as rheumatoid arthritis are complex multifactorial disorders that are chronic in nature and debilitating for patients. A number of drug families are available to clinicians to manage these disorders but few tests exist to target these to the most responsive patients. As a consequence, drug failure and switching to drugs with alternate modes of action is common. In parallel, a limited number of laboratory tests are available which measure biological indicators or ‘biomarkers’ of disease activity, autoimmune status, or joint damage. There is a growing awareness that assimilating the fields of drug selection and diagnostic tests into ‘companion diagnostics’ could greatly advance disease management and improve outcomes for patients. This review aims to highlight: the current applications of biomarkers in rheumatology with particular focus on companion diagnostics; developments in the fields of proteomics, genomics, microbiomics, imaging and bioinformatics and how integration of these technologies into clinical practice could support therapeutic decisions.

KW - Bioinformatics

KW - Companion Diagnostics

KW - Genomics ,

KW - Microbiomics

KW - Stratified Medicine

KW - Arthritis

U2 - 10.1586/14737159.2015.969244

DO - 10.1586/14737159.2015.969244

M3 - Article

VL - 15

JO - Expert Review of Molecular Diagnostics

T2 - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 2

ER -